<DOC>
	<DOCNO>NCT00658671</DOCNO>
	<brief_summary>A dose-escalation trial design assess safety tolerability treatment ENMD-2076 administer orally range dos patient advance cancer refractory current treatment curative therapy exists .</brief_summary>
	<brief_title>A Dose-Escalation Study ENMD-2076 Administered Orally Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histologic proof advance cancer progress treatment standard therapy curative provide clinical benefit . Meet modify RECIST Criteria disease follow clinical benefit . Are great equal 18 year age . AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ ULN Creatinine ≤ 1.5 x ULN Absolute neutrophil count ≥ 1500 cells/mm3 Platelets ≥ 100,000/mm3 Hemoglobin ≥ 9.0 g/dL Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Agree use effective contraceptive method prior study entry , study participation , least 30 day last administration study medication . Have ability understand requirement study , provide write informed consent include authorization release protect health information , abide study restriction , agree return require assessment . Women pregnant nursing . Have receive radiotherapy chemotherapy less two week prior first dose study medication recover acute toxicity prior treatment . Have participate clinical trial involve conventional investigational drug within 28 day prior initiation ENMD2076 dosing . Have active , acute , chronic clinically significant infection . Have uncontrolled severe hypertension congestive heart failure . Have active angina pectoris recent myocardial infarction ( within 6 month ) . Have chronic atrial fibrillation QTc great 470 msec . Have major surgery within 21 day start therapy . Have plan surgical treatment tumor ( ) Have additional uncontrolled serious medical psychiatric illness . Have medical condition would impair administration oral agent include significant bowel resection , inflammatory bowel disease uncontrolled nausea vomiting . Have 2+ protein urinalysis history nephrotic syndrome . Known central nervous system metastasis . Have history deep vein thrombosis pulmonary embolus , unless receive therapeutic anticoagulation warfarin lowmolecularweight heparin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>